tiprankstipranks
Cartesian Therapeutics Reports Promising Phase 2b Trial Results
Company Announcements

Cartesian Therapeutics Reports Promising Phase 2b Trial Results

Cartesian Therapeutics ( (RNAC) ) has provided an update.

Pick the best stocks and maximize your portfolio:

Cartesian Therapeutics announced promising results from its Phase 2b trial of Descartes-08, an mRNA cell therapy for myasthenia gravis (MG), showcasing deep, durable responses without preconditioning chemotherapy. The company plans to start a Phase 3 AURORA trial in 2025, focusing on the improvement of daily living activities in MG patients. The therapy was well-tolerated in outpatient settings, with no severe adverse effects, highlighting its potential as a significant treatment advancement for MG.

For detailed information about RNAC stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyCartesian Therapeutics price target raised to $45 from $41 at H.C. Wainwright
TheFlyCartesian Therapeutics reports positive updated Phase 2b results in myasthenia
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App